Novogen Ltd. (Nasdaq: NVGN) announced that its TRXE-009 had been highly
effective against melanoma in pre-clinical studies. Shares of the
pharmaceutical more than tripled by leaping $3.67 to close at $5.38.
Novogen reports upbeat preclinical results
December 16, 2014 at 18:25 PM EST